169 related articles for article (PubMed ID: 37349644)
41. CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal squamous cell carcinomas.
Fang J; Ma Y; Li Y; Li J; Zhang X; Han X; Ma S; Guan F
Mol Carcinog; 2022 Nov; 61(11):1043-1055. PubMed ID: 36102200
[TBL] [Abstract][Full Text] [Related]
42. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes.
Kuo IY; Huang YL; Lin CY; Lin CH; Chang WL; Lai WW; Wang YC
J Biomed Sci; 2019 Feb; 26(1):20. PubMed ID: 30777052
[TBL] [Abstract][Full Text] [Related]
43. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
[TBL] [Abstract][Full Text] [Related]
44. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2.
Zhang Z; Xiong R; Li C; Xu M; Guo M
Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):826-833. PubMed ID: 31287493
[TBL] [Abstract][Full Text] [Related]
45. Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma.
Mizumoto A; Ohashi S; Kamada M; Saito T; Nakai Y; Baba K; Hirohashi K; Mitani Y; Kikuchi O; Matsubara J; Yamada A; Takahashi T; Lee H; Okuno Y; Kanai M; Muto M
J Gastroenterol; 2019 Aug; 54(8):687-698. PubMed ID: 30737573
[TBL] [Abstract][Full Text] [Related]
46. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
[TBL] [Abstract][Full Text] [Related]
47. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation.
Jing C; Li X; Zhou M; Zhang S; Lai Q; Liu D; Ye B; Li L; Wu Y; Li H; Yue K; Chen P; Yao X; Wu Y; Duan Y; Wang X
Theranostics; 2021; 11(12):5847-5862. PubMed ID: 33897885
[TBL] [Abstract][Full Text] [Related]
48. Krüppel-Like Factor 4 Enhances Sensitivity of Cisplatin to Esophageal Squamous Cell Carcinoma (ESCC) Cells.
Chen C; Ma Z; Zhang H; Liu X; Yu Z
Med Sci Monit; 2017 Jul; 23():3353-3359. PubMed ID: 28694421
[TBL] [Abstract][Full Text] [Related]
49. Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer.
Sawayama H; Ogata Y; Ishimoto T; Mima K; Hiyoshi Y; Iwatsuki M; Baba Y; Miyamoto Y; Yoshida N; Baba H
Cancer Sci; 2019 May; 110(5):1705-1714. PubMed ID: 30861255
[TBL] [Abstract][Full Text] [Related]
50. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
[TBL] [Abstract][Full Text] [Related]
51. Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.
Xie X; Zu X; Liu F; Wang T; Wang X; Chen H; Liu K; Wang P; Liu F; Zheng Y; Bode AM; Dong Z; Kim DJ
Mol Carcinog; 2019 Jul; 58(7):1248-1259. PubMed ID: 31100197
[TBL] [Abstract][Full Text] [Related]
52. Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells.
Toshimitsu H; Hashimoto K; Tangoku A; Iizuka N; Yamamoto K; Kawauchi S; Oga A; Furuya T; Oka M; Sasaki K
Cancer Lett; 2004 Jul; 211(1):69-78. PubMed ID: 15194218
[TBL] [Abstract][Full Text] [Related]
53. ACP-5862 suppresses esophageal squamous cell carcinoma growth through inducing apoptosis via activation of endoplasmic reticulum stress and ROS production.
Liu Q; He J; Zhou X; Han M; Li J; Liu C; Yuan H
Biochem Biophys Res Commun; 2021 Jan; 534():995-1002. PubMed ID: 33168189
[TBL] [Abstract][Full Text] [Related]
54. Upregulation of KCNMA1 facilitates the reversal effect of verapamil on the chemoresistance to cisplatin of esophageal squamous cell carcinoma cells.
Ge N; Yang GS; Zhang TY; Chang N; Kang YH; Zhou Q; Fan PS
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1869-1880. PubMed ID: 33660797
[TBL] [Abstract][Full Text] [Related]
55. Downregulation of MUTYH contributes to cisplatin‑resistance of esophageal squamous cell carcinoma cells by promoting Twist‑mediated EMT.
Guo Y; Jia Y; Wang S; Liu N; Gao D; Zhang L; Lin Z; Wang S; Kong F; Peng C; Liu Y
Oncol Rep; 2019 Dec; 42(6):2716-2727. PubMed ID: 31578574
[TBL] [Abstract][Full Text] [Related]
56. β-elemene Suppresses Migration of Esophageal Squamous Cell Carcinoma by Modulating Expression of MMP9 through the PI3K/Akt/NF-κB Pathway.
Liang Y; Li S
Comb Chem High Throughput Screen; 2023; 26(13):2304-2320. PubMed ID: 36872359
[TBL] [Abstract][Full Text] [Related]
57. FAT1 downregulation enhances stemness and cisplatin resistance in esophageal squamous cell carcinoma.
Zhai Y; Shan C; Zhang H; Kong P; Zhang L; Wang Y; Hu X; Cheng X
Mol Cell Biochem; 2022 Dec; 477(12):2689-2702. PubMed ID: 35606602
[TBL] [Abstract][Full Text] [Related]
58. Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth.
Jia X; Wang P; Huang C; Zhao D; Wu Q; Lu B; Nie W; Huang L; Tian X; Li P; Laster KV; Jiang Y; Li X; Li H; Dong Z; Liu K
J Exp Clin Cancer Res; 2023 Apr; 42(1):97. PubMed ID: 37088855
[TBL] [Abstract][Full Text] [Related]
59. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.
Liu T; Li R; Zhao H; Deng J; Long Y; Shuai MT; Li Q; Gu H; Chen YQ; Leng AM
Oncotarget; 2016 Oct; 7(41):66851-66864. PubMed ID: 27588477
[TBL] [Abstract][Full Text] [Related]
60. Reticulocalbin3: A Ca
Cai R; Wang P; Zhao X; Lu X; Deng R; Wang X; Hong C; Lin J
Cancer Sci; 2022 Oct; 113(10):3593-3607. PubMed ID: 35839283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
